Potential role of RHO Kinase inhibitors in combating diabetes-related complications including diabetic neuropathy-A review

Current Diabetes Reviews

Volumn 9, Issue 3, 2013, Pages 249-266

  Mishra, Ram Kumar ^a   Alokam, Reshma ^a   Sriram, Dharmarajan ^a   Yogeeswari, Perumal ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Angiopathy; Cardiomyopathy; Diabetes; Diabetic complications; Erectile dysfunction; Fasudil; H1152; Nephropathy; Neuropathy; Retinopathy; Rho kinase; Rho kinase inhibitor; RhoA; ROCK; Y27632

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AS 1892802; CISPLATIN; ENALAPRIL; EXOENZYME C3; FASUDIL; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROSIGLITAZONE; SAR 407899; SIMVASTATIN; UNCLASSIFIED DRUG;

ALLODYNIA; BLADDER DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GLYCEMIC CONTROL; HUMAN; HYPERALGESIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KINESIOTHERAPY; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; NERVE REGENERATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMIDES; ANIMALS; CARDIOMYOPATHIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; HUMANS; MICE; OXIDATIVE STRESS; PYRIDINES; RATS; RHO-ASSOCIATED KINASES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

EID: 84878662222     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399811309030006     Document Type: Review

References (110)

1. World Health Organization.Prevention of diabetes mellitus. Report of a WHO Study Group. Geneva: World Health Organization; 1994. No. 844.
2. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-21.
3. Data from Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
4. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation ofdiabetic cardiomyopathy. Cardiology 2002; 98: 33-9.
5. Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia 2000; 43: 957-73.
6. Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia2005; 48: 578-85.
7. United States Renal Data System. (USRDS) 2007 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services; 2007.
8. Immune dysfunction in patients with diabetes mellitus (DM), FEMS Immunol Med Microbiol 1999; 26, 259-65.
9. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. J Am Med Assoc 2003; 289: 2265-9.
10. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999; 7:139-53.
11. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002; 287: 360-72.
12. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update.Ann Intern Med 2002; 137: 25-33.
13. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373-405.
14. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-45.
15. Hollander PA, Levy P, Fineman M, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes mellitus: A one year randomized controlled trial. Diabetes Care 2003; 26: 784-90.
16. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiledcoil forming protein serine/threonine kinase in mice. FEBS Lett1996; 392: 189-93.
17. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. DevBiol 2004; 265: 23-32.
18. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell DevBiol 2005; 21: 247-69.
19. Doran JD, Liu X, Taslimi P, Saadat A, Fox T. New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer- to-monomer transition and its kinetic implications. Biochem J 2004; 384: 255-62.
20. Kitazawa T, Eto M, Woodsome TP, Brautigan DL. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J BiolChem 2000; 275: 9897-900.
21. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J BiolChem 1996; 271: 20246-49.
22. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K.J Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. BiolChem 2000; 275: 3577-82.
23. Kaneko T, Amano M, Maeda A, et al. Identification of calponin as a novel substrate of Rho-kinase. BiochemBiophys Res Commun 2000; 273: 110-16.
24. Vahebi S, Kobayashi T, Warren CM, de Tombe PP, Solaro RJ. Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. Circ Res 2005; 96: 740-7.
25. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behavior. Nat Rev Mol Cell Biol 2003; 4: 446-56.
26. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 12: 629-35.
27. Sauzeau V, Jeune HL, Cario-Toumaniantz C, et al. Cyclic GMPdependent protein kinase signaling pathway inhibits RhoA-induced Ca+2sensitization of contraction in vascular smooth muscle. J Biol- Chem 2000; 275, 21722-9.
28. Xie Z, Su W, Guo Z, Pang H, Post SR, Gong MC. Up-regulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells. Cardiovasc Res 2006; 69: 491-501.
29. Naik JS, Xiang L, Hester RL, Enhanced role for RhoA-associated kinase in adrenergic-mediated vasoconstriction in gracilis arteries from obese Zucker rats. Am J PhysiolRegulIntegr Comp Physiol 2006; 290: R154-61.
30. Massey AR, Miao L, Smith BN, et al. Increased RhoA translocation in renal cortex of diabetic rats. Life Sci 2003; 72: 2943-52.
31. Kanda T, Wakino S, Homma K, et al. Rho-kinase as a molecular target for insulin resistance and hypertension. FASEB J 2006; 20: 169-71.
32. Peng F, Wu D, Gao B, et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008; 57: 1683-92.
33. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995; 81: 53-62.
34. Goalstone M, Kamath V, Kowluru A, Glucose activates prenyltransferases in pancreatic islet beta-cells. Biochem Biophys Res Commun 2010; 391: 895-8.
35. Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. ProcNatlAcadSci USA 1989; 86: 5141-5
36. Mehta D, Rahman A, Malik AB. Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. J BiolChem 2001; 276: 22614-20.
37. Schreibelt G, Kooij G, Reijerkerk A, et al. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J 2007; 21: 3666-76.
38. Sawada N, Itoh H, Yamashita J, et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. BiochemBiophys Res Commun 2001; 280:798-805.
39. Mustafa S, Vasudevan H, Yuen VG, McNeill JH. Renal expression of arachidonic acid metabolizing enzymes and RhoA/Rho kinases in fructose insulin resistant hypertensive rats. Mol Cell Biochem 2010; 333: 203-9.
40. Chang J, Xie M, Shah VR, et al. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. ProcNatlAcadSci USA 2006; 103: 14495-500.
41. Brown MJ, Asbury AK. Diabeticneuropathy. AnnNeurol 1984; 15: 2-12.
42. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial (DCCT) research group N Engl J Med 1993; 329: 977-86.
43. Low PA. Recent advances in the pathogenesis of diabetic neuropathy. Muscle Nerve 1987; 10: 121-8.
44. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of complications. N Engl J Med 1988; 318:1315-21.
45. Koya D, King GL. Protein kinase C and the development of diabetic complications. Diabetes 1998; 47: 859-66.
46. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. JNeuropatholExpNeurol 1996; 55: 1181-93.
47. Nakayama AY, Harms MB, Luo L. Small GTPasesRac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. J Neurosci 2000; 20: 5329-38.
48. Wang HG, Lu FM, Jin I, et al. Presynaptic and postsynaptic roles of NO, cGK, and RhoA in long-lasting potentiation and aggregation of synaptic proteins. Neuron 2005; 45: 389-403.
49. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004; 10: 712-8.
50. Tatsumi S, Mabuchi T, Katano T, et al. Involvement of Rho-kinase in inflammatory and neuropathic pain through phosphorylation of myristoylated alanine-rich C-kinase substrate (MARCKS). Neuroscience 2005; 131: 491-8.
51. Ramer LM, Borisoff JF, Ramer MS. Rho-kinase inhibition enhances axonal plasticity and attenuates cold hyperalgesia after dorsal rhizotomy. J Neurosci 2004; 24, 10796-805.
52. Ohsawa M, Mutoh J, Hisa H. Mevalonate sensitizes the nociceptive transmission in the mouse spinal cord. Pain 2008; 134: 285-92.
53. Büyükafşar K, Yalçin I, Kurt AH, Tiftik RN, Sahan-Firat S, Aksu F. Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice. Eur J Pharmacol 2006; 541: 49-52.
54. Cirino G, Fusco F, Imbimbo C, Mirone V. Pharmacology of erectile dysfunction in man. PharmacolTher 2006; 111: 400-23.
55. Goroll, Allan H, Mulley Jr., Albert G. Primary Care Medicine: Office Evaluation and Management of the Adult Patient. Lippincott Williams & Wilkins (LWW) 2009, ISBN-10: 0781775132,ISBN- 13: 9780781775137.
56. Bivalacqua TJ, Usta MF, Kendirci M, et al. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2005; 2: 187-97.
57. Chitaley K, Wingard C J, Webb RC, et al. Antagonism of Rhokinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7, 119-22.
58. Rees RW, Ralph DJ, Royle M, Moncada S, Cellek S. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol 2001; 133: 455-8.
59. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22: 8467-77.
60. Chua R, Tar M, Melman A, DiSantoME.Streptozotocin induced diabetes results in time-dependent up-regulation of the endothelin/ rho-kinase pathway in rat corpus cavernosum smooth muscle. J Sex Med 2006; 3 (Suppl 1): 25.
61. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J BiolChem 2003; 278: 9472-80.
62. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. ProcNatlAcadSci U S A 2004; 101: 9121-6.
63. Gratzke C, Strong TD, Gebska MA, et al. Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J Urol 2010; 184:2197-204.
64. Mills TM, Chitaley K, Lewis RW, Webb RC. Nitric oxide inhibits RhoA/Rho-kinase signalling to cause penile erection. Eur J Pharmacol 2002; 439: 173-4.
65. Hirose A, Tanikawa T, Mori H, Okada Y, Tanaka Y. Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. FEBS Lett 2010; 584: 61-6.
66. Chitaley K, Bivalacqua TJ, Champion HC, et al. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. BiochemBiophys. Res. Commun 2002; 298: 427-32.
67. Gojo A, Utsunomiya K, Taniguchi K, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocininduced diabetic rats. Eur J Pharmacol2007; 568: 242-7.
68. Hayashi K, Wakino S, Kanda T, Homma K, Sugano N, Saruta T: Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. J PharmacolSci 2006; 100: 29-33.
69. Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression. ExpBiol Med (Maywood) 2008; 233: 4-11.
70. Nobe K, Yamazaki T, Tsumita N, Hashimoto T, Honda K. Glucose-dependent enhancement of diabetic bladder contraction is associated with a rho kinase-regulated protein kinase C pathway. J PharmacolExpTher 2009; 328: 940-50.
71. Masago T, Watanabe T, Saito M, Kinoshita Y, Sato K, Miyagawa I. Effect of the rho-kinase inhibitor hydroxyfasudil on bladder overactivity: an experimental rat model. Int J Urol 2009; 16: 842-7.
72. Arita R, Hata Y, Ishibashi T. ROCK as a Therapeutic target of Diabetic Retinopathy. J Ophthalmol 2010; 2010: 175163.
73. van NieuwAmerongen GP, van Delft S, Vermeer MA, Collard JG, van Hinsbergh VW. Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ Res 2000; 87: 335-40
74. van NieuwAmerongen GP, Beckers CM, Achekar ID, Zeeman S, Musters RJ, van Hinsbergh VW. Involvement of Rho kinase in endothelial barrier maintenance. ArteriosclerThrombVascBiol 2007; 27: 2332-9.
75. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001; 42: 137-44.
76. Hein TW, Rosa RH Jr, Yuan Z, Roberts E, Kuo L. Divergent roles of nitric oxide and rho kinase in vasomotor regulation of human retinal arterioles. Invest Ophthalmol Vis Sci. 2010; 51: 1583-90.
77. Lin G, Craig GP, Zhang L, et al. Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc Res 2007; 75: 51-8.
78. Teixeira CE, Ying Z, Webb RC. Proerectile effects of the Rhokinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl) sulfonyl]homopiperazine (H-1152) in the rat penis. J Pharmacol Exp Ther 2005; 315: 155-62.
79. Tang J, Fitzgerald SM, Boughtman BN, Cole S.W, Brands M.W, Zhang JH. Decreased RhoA expression in myocardium of diabetic rats. Can J Physiol Pharm 2005; 83: 775-83.
80. Soliman H, Craig GP, Nagareddy P, et al. Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats. Cardiovasc Res 2008; 79: 322-30.
81. Ren J, Duan J, Thomas DP, et al. IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. Am J PhysiolRegulIntegr Comp Physiol 2008; 294: R793-802.
82. Hata Y, Miura M, Nakao S, Kawahara S, Kita T, Ishibashi T. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor. Jpn J Ophthalmol 2008; 52: 16-23.
83. Nishikawa Y, Doi M, Koji T, et al. The role of rho and rhodependent kinase in serotonin-induced contraction observed in bovine middle cerebral artery. Tohoku J Exp Med 2003; 201: 239-49.
84. Abe M, Inoue D, Matsunaga K, et al. Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells. J Cell Physiol 2002; 190: 109-16.
85. van NieuwAmerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. ArteriosclerThrombVascBiol 2003; 23: 211-7.
86. Kroll J, Epting D, Kern K, et al. Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis. Am J Physiol Heart CircPhysiol 2009; 296: H893-9.
87. James SE, Dunham M, Carrion-Jones M, Murashov A, Lu Q. Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin. Neurotoxicology 2010; 31: 188-94.
88. Yoshimi E, Yamamoto H, Furuichi Y, Shimizu Y, Takeshita N. Sustained analgesic effect of the Rho kinase inhibitor AS1892802 in rat models of chronic pain. J PharmacolSci 2010; 114: 119-22.
89. Ohsawa M, Aasato M, Hayashi SS, Kamei J. RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice. Pain 2011; 152: 114-22.
90. Jin L, Burnett AL. RhoA/Rho-kinase in erectile tissue: mechanisms of disease and therapeutic insights. ClinSci (Lond) 2006; 110: 153-65.
91. Kikuchi Y, Yamada M, Imakiire T, et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin- resistant diabetic rats. J Endocrinol2007; 192: 595-603.
92. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57: 714-23.
93. Löhn M, Plettenburg O, Ivashchenko Y, et al. Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009; 54: 676-83.
94. Nagaoka T, Hein TW, Yoshida A, Kuo L. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways. Invest Ophthalmol Vis Sci 2007; 48: 825-32.
95. Kawahara S, Hata Y, Kita T, et al. Potent inhibition of cicatricial contraction in proliferative vitreo retinal diseases by statins. Diabetes 2008; 57: 2784-93.
96. Yamaguchi H, Kasa M, Amano M, Kaibuchi K, Hakoshima T. Molecular mechanism for the regulation of Rho-kinase by dimerization and its inhibition by Fasudil. Structure 2006; 14: 589-600.
97. Yamaguchi H, Miwa Y, Kasa M, et al. Structural basis for inducedfit binding of Rho-kinase to the inhibitor Y-27632. J Biochem 2006; 140: 305-11.
98. Dvorsky R, Blumenstein L, Vetter IR, Ahmadian MR. Structural insights into the interaction of ROCKI with the switch regions of RhoA. J Biol Chem 2004; 279: 7098-104.
99. Wang Dong-Hua, Qu Wan-Lu, Shi Liu-Qing, Wei J. Molecular docking and pharmacophore model studies of Rho kinase inhibitors. Mole Simul 2011; 37: 488-94.
100. Accelrys, Inc.10188 Telesis Court, Suite 100San Diego, CA 92121USA.
101. Gong LL, Fang LH, Peng JH, Liu AL, Du GH. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors. J Biotechnol 2010; 145: 295-303.
102. Montes M, Miteva MA, Villoutreix BO. Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections. Proteins 2007; 68: 712-25.
103. Qin J, Lei B, Xi L, Liu H, Yao X. Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis. Eur J Med Chem 2010; 45: 2768-76.
104. Takami A, Iwakubo M, Okada Y, et al. Design and synthesis of Rho kinase inhibitors (I). Bioorg Med Chem 2004; 12: 2115-37.
105. SYBYL software package, Tripos Inc., 1699 South Hanley Rd., St. Louis, MO 63144, USA.
106. Iwakubo M, Takami A, Okada Y, et al. Design and synthesis of Rho kinase inhibitors (II). Bioorg Med Chem 2007; 15: 350-64.
107. Iwakubo M, Takami A, Okada Y, et al. Design and synthesis of rho kinase inhibitors (III). Bioorg Med Chem 2007; 15: 1022-33.
108. Goodman KB, Cui H, Dowdell SE, et al. Development of dihydropyridoneindazole amides as selective Rho-kinase inhibitors. J Med Chem 2007; 50:6-9.
109. Stavenger RA, Cui H, Dowdell SE, et al. Discovery of aminofurazan- azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J Med Chem 2007; 50:2-5.
110. Fang X, Yin Y, Chen YT, et al. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem 2010; 53: 5727-37.